

1 Diffusion-driven enhancement of the antibiotic 2 resistance selection window

3 Ayari Fuentes-Hernández^{1,*}, Anastasia Hernández-Koutoucheva^{1,†}, Alán F. Muñoz^{1,†},
4 Raúl Domínguez Palestino^{1,†}, and Rafael Peña-Miller¹

5 ¹ Laboratorio de Biología Sintética y de Sistemas, Centro de Ciencias Genómicas, Universidad Nacional Autónoma
6 de México, 62210, Cuernavaca, México

7 *Corresponding author: ayarifh@ccg.unam.mx

8 [†]These authors contributed equally to this work

9 ABSTRACT

The current crisis of antimicrobial resistance in clinically-relevant pathogens has highlighted our limited understanding of the ecological and evolutionary forces that drive drug resistance adaptation. For instance, although human tissues are highly heterogeneous, most of our mechanistic understanding about antibiotic resistance evolution is based on constant and well-mixed environmental conditions. A consequence of considering spatial heterogeneity is that, even if antibiotics are prescribed at high dosages, the penetration of drug molecules through tissues inevitably produces antibiotic gradients, exposing bacterial populations to a range of selective pressures and generating a dynamic fitness landscape that changes in space and time. In this paper, we will use a combination of mathematical modelling and computer simulations to study the population dynamics of susceptible and resistant strains competing for resources in a network of micro-environments with varying degrees of connectivity. Our main result is that highly-connected environments increases diffusion of drug molecules, enabling resistant phenotypes to colonize a larger number of spatial locations. We validated this theoretical result by culturing fluorescently-labelled *Escherichia coli* in 3D-printed devices that allow us to control the rate of diffusion of antibiotics between neighbouring compartments and quantify the spatio-temporal distribution of resistant and susceptible bacterial cells.

11 Keywords: antibiotic resistance, spatial structure, mathematical modelling, 3D printing

12 Introduction

13 The introduction of antimicrobial substances as therapeutic agents has had a dramatic effect in decreasing
14 mortality and morbidity associated with infectious diseases. However, the indiscriminate use of these
15 substances, in conjunction with the accelerated rate of adaptation exhibited by pathogenic bacteria, has
16 dramatically reduced the efficacy of antimicrobial therapies and presents us with the possibility of a
17 health-care crisis of catastrophic dimensions.¹ In this context, it is necessary to invest in the discovery of
18 new drugs² and to reduce the use of antimicrobial substances, both in the clinic³ and elsewhere,⁴ but also
19 to increase our understanding about the complex interaction between antibiotics, bacteria and hosts.

20 Of course, the ultimate goal of antimicrobial therapy is to drive a pathogenic population to extinction, so

antibiotics must be prescribed at concentrations high enough for bacterial cells to die. Even if complete clearance of pathogens cannot be achieved, conventional wisdom states that high drug dosages suppress growth of the bacterial population and adjuvate the immune system to control the infection. Another benefit of maximizing the inhibitory effect of antibiotics, is that, in principle, the mutational supply is reduced and therefore the probability that an individual in the population acquires an antibiotic-resistance mutation is lower⁵ (although studies have shown that mutation rates can be density-dependant⁶ and increased in the presence of antimicrobial substances⁷).

But aggressive antibiotic protocols can accelerate the rate of adaptation, for instance by suppressing susceptible competitors and releasing resources that promote growth of the resistant subpopulation.⁸ Motivated by the evident failure of the current ‘*hit early, hit hard*’ prescription strategy,⁹ a series of theoretical and experimental studies have argued that antimicrobial therapies should consider resistance management instead of focusing exclusively in pathogenic clearance, for example by using shorter¹⁰ and less aggressive¹¹ treatments, multidrug combination therapies,^{12,13} sequential treatments^{14–16} and increasing drug appropriateness with better point-of-care diagnostic tests.^{17,18}

Another problem associated with the use of high doses of antibiotics is that, even if a lethal drug concentration is administered, a heterogeneous spatial structure will produce an antibiotic gradient and thus expose the pathogenic bacteria to a range of selective pressures in favour of resistance. Indeed, it is well known that the therapeutic use of antibiotics sees *in vivo* drug concentrations sweep from high-concentrations downwards during treatment (with a considerable time spent at low drug concentrations,² producing low-dose sanctuaries that have been observed in bacterial¹⁹ and viral infections,²⁰ promoting the evolution of antibiotic resistance.²¹ For this reason, previous studies have focused on evaluating the effect of sub-lethal doses in the evolution of drug resistance²² and in modulating virulence factors,²³ showing that selection for resistance can occur at very low antibiotic doses^{24,25} and that antibiotic gradients can accelerate the rate of drug-resistance adaptation.^{26–28} Similarly, convection²⁹ and cell migration¹³ can lead to increases in drug resistance through sequential adaptive steps in space and time.

As the ecological and evolutionary dynamics of a microbial community depend on the genotypic and functional complexity of the population and their interaction with the environment,³⁰ then the chemical composition of the media is a key driver of microbial ecological and evolutionary dynamics. Crucially, this is modified by the physical properties of the environment, for instance its temperature³¹ and humidity,³² but also by structural properties like geometry³³ and porosity.³⁴ In this paper, we will argue that the connectivity between different spatial locations is directly responsible for the distribution of antibiotics in the environment, thus producing a range of selective pressures in favour of resistance.

In short, we will use a population dynamics model to argue that selection for resistance is correlated with the degree of connectivity of the environment, both in a linear array of connected micro-environments and also in networks with different topological properties. This prediction will be validated empirically using an experimental model system based on spatially-explicit culture devices built using computer aided design software and 3D printing technology. These devices allow us to control the rate of diffusion of drug molecules between neighbouring micro-environments, while quantifying spatio-temporal changes in the relative frequency of fluorescently-tagged resistant and susceptible *Escherichia coli* strains.

Results

Competitive fitness in a range of drug concentrations

In this paper we will use two strains of *E. coli* MC4100:^{35,36} WCL, a strain carrying Km^R , a gene that provides resistance to the aminoglycoside antibiotic Kanamycin, and GBY, a susceptible strain that lacks Km^R . All experiments were conducted using M9 minimal media supplemented with 0.4% of glucose and 0.2% of casaminoacids. Furthermore, each bacterial strain is tagged with a different fluorescent marker under a chromosomal constitutive promoter (WCL with CFP and GBY with YFP), allowing us to use a fluorescent spectrophotometer to quantify the intensities of both fluorescent channels and use this information to estimate the relative abundances of each strain in a mixed population.

Our main objective is to identify the range of drug concentrations where antibiotic resistance is positively selected for. To achieve this goal, we first need to evaluate the fitness advantage associated with carrying a drug-resistant gene, a property that can be estimated using a pair-wise competition experiment that directly compares the fitness of the drug-resistant genotype with respect to the susceptible strain. This can be achieved using a standard protocol in experimental microbiology that consists on growing both strains in controlled environmental conditions for T units of time (usually 24 hours), and then estimating the relative abundances of each bacterial subpopulation using a fluorescent spectrophotometer, a flow cytometer or replica plating with selective media. From the relative frequency of each strain at the end of the experiment we can then define the following *relative fitness* coefficient:

$$\phi_r := \phi_r(A) = \frac{\ln(B_s(T)/B_s(0))}{\ln(B_r(T)/B_r(0))}, \quad (1)$$

where $B_r(t)$ and $B_s(t)$ denote the densities of resistant and susceptible strains, respectively, and A the environmental concentration of the antimicrobial substance (in our case, Kanamycin). For the purpose of this paper, we will consider that $B_r(0) = B_s(0)$, an assumption that allows us to estimate $\phi_r(A)$ based only in observations about the state of the system at the end of the experiment.

Figure 1B shows the optical densities of both bacterial strains after 24 hours of growing in rich media (LB) in the absence of antibiotics, both in co-culture and in isolation. Note that growth of the resistant mono-culture (cyan bar) is lower than that of the susceptible bacteria (yellow), implying that Kanamycin resistance is associated with a fitness burden in drug-free environments.³⁷ As a result, the susceptible strain has a higher competitive fitness than the resistant sub-population at low antibiotic concentrations, a feature represented by the inequality $\phi_r < 1$.

In contrast, if the concentration of antibiotic is high, then the advantage of carrying a resistance mutation outweighs its fitness burden and therefore $\phi_r(A)$ is a monotonously increasing function of antibiotic dose (see Figure 1A). If we denote with A_{MSC} the antibiotic concentration such that $\phi_r(A) > 1$ for all $A > A_{MSC}$, then we can identify the range of drug concentrations whereby resistance is positively selected for. This critical concentration is referred to in the literature as the *Minimal Selection Concentration*²⁴ (MSC).

In order to study how the local strength of selection for resistance changes in an antibiotic gradient, we use a dose-response experiment that consists on growing cells under increasing drug concentrations and measuring bacterial densities or maximal growth rates in a fixed time interval. This assay is routinely used in medical microbiology to estimate drug concentrations that completely inhibit growth of a specific clinical isolate and, for this reason, dose-response experiments are usually performed with mono-cultures. In our experiments, we inoculate the dose-response experiment with both strains, with the aim of computing $\phi_r(A_i)$ for a range of drug concentrations $A_1 < A_2 < \dots < A_i < \dots < A_n$.

Another critical antibiotic concentration is known as the *Minimum Inhibitory Concentration* (MIC), defined as the drug concentration such that bacterial growth is completely suppressed. In general, the shape of dose-response curves can be approximated with a logistic equation. Indeed, Figure 1D shows that total bacterial density remains constant at sub-MIC concentrations, but relative abundances of each subpopulation change as a function of dose, with B_r increasing in frequency as the concentration of drug increases. The region in drug-space where bacterial growth is still observed (*i.e.* $\frac{d}{dt}B_r > 0$) and drug resistance is under positive selection (*i.e.* $\phi_r(A) > 1$), is known as the *Mutant Selection Window* (MSW).³⁸

An interesting observation obtained by comparing Figures 1C and 1D, is that the MIC of the co-culture corresponds to the MIC of the resistant subpopulation, while the susceptible strain has, by definition, a lower MIC. Interestingly, in our experiments, bacterial density seems to be maximized at intermediate drug concentrations, a feature that has been reported previously³⁹ and can have many causes, including B_r growing without competition at intermediate drug concentrations.⁴⁰ Indeed, Figure 1C and 1D show that there




Figure 1. Effect of antibiotic concentration in a competition experiment between resistant (WCL, CFP) and susceptible (GBY, YFP) strains. A) Relative fitness as a function of Kanamycin concentration, in co-culture. B) Optical density of each strain, on isolation and co-culture. Growth of the susceptible strain is larger compared to the resistant subpopulation. C) Normalized fluorescent intensity measured under a range of drug concentrations. D) Mean optical density of the co-culture obtained in a dose-response experiment where the total bacterial density decreases as the concentration of antibiotics increases (C). Concurrently, the fraction of the population that is drug-resistant becomes larger (D).

125 is a range of concentrations where B_s has already gone extinct, but the concentration is not high enough
 126 to suppress growth of the resistant subpopulation. Note that, in clinical settings, this is the region of
 127 drug-space that we would like to avoid in order to promote the evolution of drug resistance.

128 **Modeling drug-resistance population dynamics**

129 Previous studies have used a *top-down* approach and postulated pharmacodynamic models derived from
 130 fitting dose-response curves with Hill functions.^{41,42} Instead, here we will use a *bottom-up* approach that
 131 explicitly considers the concentrations of limiting resource and antibiotics present in the environment,
 132 with the aim of evaluating the population dynamics between susceptible and resistant bacterial types
 133 that emerges in response to different environmental conditions. In the following section we will discuss
 134 how to include the spatial component into the model, but first let us assume that the environment is
 135 well-mixed and, therefore, the interaction between bacterial cells and abiotic molecules follows a mass
 136 action kinetics so we can model temporal changes in bacterial abundances using a system of ordinary
 137 differential equations.

138 Although clearly a possibility, for the purpose of this paper we will not consider that susceptible cells
 139 can acquire drug resistance through stochastic mutations or horizontal gene transfer. The reason for
 140 this assumption is that we are mainly interested in studying the ecological dynamics of the system after
 141 a resistant mutant appears in the population. Therefore, both in our numerical simulations and in the
 142 experiments discussed later in this paper, we will consider that both strains are *a priori* present in the
 143 system the moment the antibiotic is deployed and quantify the strength of selection for resistance, $\phi_r(A)$,
 144 in response to a range of antibiotic concentrations.

First, let us represent the concentration of a limiting resource present in the environment with the variable $R(t)$. Then uptake of resources into each cell can be modeled with a non-linear saturating resource uptake function that depends on $R(t)$:

$$U_*(R(t)) = \frac{\mu_{max}^* R(t)}{K_m^* + R(t)}, \quad (2)$$

145 where μ_{max}^* and K_m^* denote the maximum uptake rate and the half-saturation constants, respectively, of
 146 bacterial type B_* .

Now let us suppose that, at time t , the environment contains an antibiotic at a concentration that we will denote $A(t)$. In particular, we will consider an antibiotic with a bacteriostatic mode of action, namely that it inhibits bacterial growth by interfering with protein translation, DNA replication, or other aspects of bacterial cellular metabolism. As mentioned before, in the experiments presented in this paper we are using Kanamycin, an aminoglycoside that binds to the 30S subunit of the ribosome, thereby suppressing bacterial protein synthesis and inhibiting growth. Therefore, we will model growth inhibition with a monotonously decreasing function, such that $\gamma(A(t)) \geq 0$ for all A , and with $\gamma(0) = 1$ in the absence of antibiotic, for instance,

$$\gamma(A) = 1 - \frac{k_1 A}{1 + k_2 A},$$

147 where parameters k_1 represent the cell's affinity for the antibiotic and k_2 the maximal growth inhibition

by the bacteriostatic drug.⁴³ Also, we will consider that α_s and α_r are parameters that represent the inactivation of drug molecules for each bacterial strain as a result of their binding with the cellular targets.

Then bacterial growth rate of bacterial type B_* can be modeled as the resource uptake function multiplied by the inhibition coefficient, $G_*(R,A) = \rho_* \cdot \gamma_*(A) \cdot U_*(R)$, where ρ_* denotes a resource conversion coefficient that represents the efficiency of each subpopulation in converting resource molecules into biomass.

So, if $x(t) = (R(t), A(t), B_s(t), B_r(t))$ represents the state of the system, the system of equations that describe its temporal dynamics can be written as:

$$\frac{dR}{dt} = -U_s(R)B_s - U_r(R)B_r \quad (3a)$$

$$\frac{dA}{dt} = -A(\alpha_s B_s + \alpha_r B_r) \quad (3b)$$

$$\frac{dB_s}{dt} = G_s(R,A)B_s \quad (3c)$$

$$\frac{dB_r}{dt} = G_r(R,A)B_r \quad (3d)$$

with initial conditions $x(0) = (R^0, A^0, B_s^0, B_r^0)$.

Figure 2 shows numerical simulations of this model with different initial drug concentrations and parameter values described in Table 1 (solved using standard ODE solvers in Matlab). Note how at low antibiotic concentrations, B_s has a higher growth rate than B_r and therefore the yellow area is larger than the blue area. As the concentration of antibiotic increases, so does the competitive fitness of the resistant strain until eventually the susceptible strain is no longer able to grow and the population is entirely composed of resistant cells (blue area). At very high drug concentrations, neither of the strains can grow and the bacterial population is completely suppressed.




Figure 2. Numerical simulations of equations 3a-d with parameters described in Table 1. Each box shows a plot of bacterial density as a function of time (black line), with the density of resistant and susceptible sub-populations represented as stacked areas (B_r in blue and B_s in yellow). The environmental concentration of antibiotic doubles from left to right. We notice that, as expected, total bacterial density decreases as the concentration of antibiotic is incremented, but the frequency of resistance in the population is positively correlated with antibiotic dose.

Modelling diffusion of antibiotics in connected micro-environments

The model presented in the previous section assumes a uniform distribution of cells and abiotic molecules in the environment. This is, of course, a simplification, as natural environments like the human body are not homogeneous, but instead can be approximated with a series of discretely-distributed compartments.⁴⁴

It is known that complex population dynamics can emerge from the mosaic of selective pressures imposed by a spatially structured environment, with separate locations selecting for specific gene variants.⁴⁵ Previous studies have also shown that drugs have characteristic penetration profiles through the tissue, thus creating antibiotic gradients and exposing bacterial populations to a range of antibiotic concentrations²¹ and, as a result, producing dynamic drug resistance fitness landscapes.^{41,46}

For the purpose of this paper we will consider that the environment consists of a network of connected micro-environments, each occupied by a polymicrobial community composed of susceptible and resistant strains. We will consider that abiotic substances (e.g. antibiotics and glucose) can diffuse between adjacent micro-environments, but with limited movement of cells between neighbouring colonies. This is a strong assumption, but one that will allow us to argue that, even without considering cell migration, selection for resistance is enhanced in environments with a high degree of connectivity.

So, let us define E as the spatial location where a group of cells interact with the extracellular environment. We will refer to this quasi-homogeneous region as a micro-environment or a compartment. Then we can model the population dynamics that occurs in each compartment using Equations (3a-3d), but with drug molecules diffusing between adjacent micro-environments. Therefore if δ_A represents the antibiotic diffusion rate and $\sigma_{i,j}$ the degree of connectivity between compartments E^i and E^j , then the concentration of antibiotic in E^i can be denoted by A^i and modeled by the following differential equation:

$$\frac{dA^i}{dt} = -A^i(\alpha_s G_s(R^i) + \alpha_r G_r(R^i)) + \sum_{n=1}^N \sigma_{i,n} (A^n - A^i) \delta_A, \quad (4)$$

where N represents the total number of micro-environments in the system ($\sigma_{i,j} = 0$ when E^i and E^j are not connected). Similarly, we will also consider that resources can diffuse between micro-environments at a rate δ_R . Therefore the differential equation that describes the rate of change of resource concentration in E^i is

$$\frac{dR^i}{dt} = -U_s(R^i)B_s^i - U_r(R^i)B_r^i + \sum_{n=1}^N \sigma_{i,n} (R^n - R^i) \delta_R. \quad (5)$$

We would expect that, if a lethal concentration of antibiotic is deployed in a node of the network, the antibiotic concentration in a different location (and thus the strength of selection in favour of the resistant subpopulation in that micro-environment), will depend on the drug concentration used, but also on the distance to the antibiotic source.

Dynamics of drug resistance in antibiotic gradients

In order to evaluate how the degree of connectivity of the network correlates with the overall strength of selection for resistance, first we will consider that the environment is composed of a linear array of

connected micro-environments. We will then solve numerically Equation 3a-d to evaluate the population dynamics that emerges in each micro-environment in response to an antibiotic gradient. For simplicity, we will consider that all consecutive micro-environments are at the same distance of each other, that is $\sigma_{i,i+1} \equiv \sigma$. In contrast, $\sigma_{i,j} \equiv 0$ if compartments E_i and E_j are not consecutive.

As we are using a lethal antibiotic concentration, in the vicinity of the location where the drug was applied, bacterial growth was completely inhibited. In contrast, micro-environments far away from the drug source present very low antibiotic concentrations and thus susceptible bacteria grow until carrying capacity. These low-dose compartments are referred to in previous studies as drug sanctuaries.²¹ At intermediate drug concentrations, however, the resistant subpopulation has a fitness advantage over the susceptible strain, $\phi_r > 1$.




Figure 3. Numerical simulations of micro-environments with varying degrees of connectivity in a linear array. A) Population dynamics of resistant and susceptible bacteria in different micro-environments. The diameter is proportional to the total bacterial density, while the relative fitness measured at the end of the experiment is color-coded (yellow represents that susceptible bacteria have a higher fitness and cyan that antibiotic resistance is positively selected for). Each row corresponds to a different degree of connectivity (illustrated as a change on width), from no connection (bottom row) to a high-degree of connectivity (top row). A lethal dose of antibiotics is deployed in the left-most column and hence, the horizontal axis represents the distance to the drug source. B) Proportion of micro-environments where the resistant bacteria have a higher fitness than the susceptible subpopulation (relative fitness $\phi_r > 1$). Note how, as the degree of connectivity increases, the number of compartments where resistant cells are selected for also increases. C) Total bacterial density as a function of connectivity degree. Although a monotonously decreasing function is observed (black line), the fraction of resistant cells in the population increases (cyan line).

194 Note that although the total concentration of antibiotic used is the same in all our numerical experiments,
195 the number of micro-environments where $\phi_r > 1$, that is the Mutant Selection Window, is higher in
196 environments with high degree of connectivity. This is illustrated in Figure 3A, where it shows that if
197 we increase σ , the number of compartments where $\phi_r > 1$ (blue circles) increases. Indeed, Figure 3B
198 shows that the number of micro-environments where the resistant strain outcompetes the susceptible
199 subpopulation appears to be positively correlated with the degree of connectivity of the environment. Also,
200 as a result of more antibiotic diffusing out of the source into the neighbouring compartments, the total
201 bacterial density observed in all compartments decreases as we increase σ . This in turn is correlated with
202 an increase in the total frequency of resistance in the population, as illustrated in Figure 3C.

203 To investigate whether the enhanced diffusion of antibiotics produces increased selection for resistance, we
204 will probe *in vitro* how antibiotic gradients modulate the fitness landscape of a population of resistant and
205 susceptible bacteria. In particular, first we will consider a linear array of connected micro-environments
206 with a lethal dose of antibiotic deployed in a single node. As expected, the antibiotic diffuses to the
207 adjacent compartments, thus producing a drug gradient. Note that we can modify the gradient formed by
208 increasing the connectivity between adjacent nodes.

209 It was recently shown that 3D printing can be performed in sterile conditions,⁴⁷ so we designed a protocol
210 that implements gradient devices printed in polylactic acid (PLA). In particular, we printed a linear array
211 of micro-environments connected through channels that restrain movement of bacterial cells, but allow
212 diffusion of antibiotic molecules between connected compartments (see Figure 4A for an illustration of
213 these devices). To characterize the gradient formed on these micro-environments, we printed a series of
214 devices composed of wells connected through channels of different widths (1, 3, and 5 mm) and filled
215 each well with 200 μ L of soft M9 agar. We then applied a fluorescent dye to the first well and, using
216 a fluorescence imaging system, estimated the concentration of dye in each compartment. As expected,
217 antibiotic diffused out of the antibiotic source and a gradient was formed after 48 hours (illustrated in
218 Figure 4B).

219 Once we established that the 3D-printed device can produce different gradients depending on the width of
220 the channels, we then proceeded to produce an antibiotic gradient by filling the first well of each device
221 with soft M9 agar and 50 μ g/ml of Kanamycin. We allowed the plate dry and then filled the rest of the
222 wells with 200 μ L of soft M9 agar (without antibiotic) and placed the device at 4°C for 48 hrs for the drug
223 gradient to form.

224 The competition assay consisted in inoculating each well in the device with 10 μ L of bacterial culture
225 (on a mixture of 1:1 ratio of susceptible and resistant bacteria) and placing the device inside a petri dish,
226 sealing it with parafilm and incubating it at 30°C for 24 hrs. As a control we also used a susceptible,
227 non-fluorescent *E. coli* MG1655 strain. In order to characterize and calibrate the profile of fluorescence
228 generated by each genotype, we inoculated each strain in isolation and measured the fluorescence intensity
229 observed using different optical configurations. As expected, Figure 4C shows that GBY can be detected
230 using YFP filters and WCL with CFP filters. When cells are in co-culture, we detected fluorescence in both
231 channels and use the maximum and minimum fluorescence observed by each strain grown in isolation to
232 normalize the fluorescence of the mixed population (see Methods for experimental details). We argue that
233 the obtained relative fluorescence is a proxy for the relative abundances of each strain in the population.




Figure 4. Experimental results. A) CAD design of linear arrays of connected micro-environments with different degrees of connectivity. B) A gradient is formed after using a green fluorescent dye (pyranine) in the bottom compartment. Each column corresponds to a photograph of the device at different time-points. C) Fluorescent intensity estimated using different fluorescence channels, both in mono-culture and in co-culture, of cells grown in the absence of antibiotics. D) Growth of a mixed population after 24 hours in the devices depicted in A). Kanamycin is deployed in the left-most well and each well is inoculated with equal proportion of resistant and susceptible strains. The top two rows illustrate different channel widths between micro-environments (channels and well edges annotated with yellow lines), allowing the diffusion of antibiotic molecules between consecutive wells. Note how, as we increase connectivity, there are more wells whereby susceptible bacteria are outcompeted by the resistant strain (blue wells). The bottom row illustrates a control experiment where micro-environments are not connected, so the antibiotic is only present in the first well and therefore the remaining compartments are colonized by susceptible bacteria (yellow wells). E) Relative frequency of susceptible bacteria (estimated using flow cytometry) observed in each micro-environment, as a function of the distance to the antibiotic source. F) Using image processing we estimated the relative fluorescence of each channel and validated the visible pattern observed in D); as the width of the channel increases, so does the number of compartments where the resistant strain (blue area) outcompetes the susceptible genotype (yellow area).

Figure 4D shows a photograph taken after 24 hours using both CFP and YFP fluorescent channels; yellow compartments correspond to micro-environments where the susceptible subpopulation outcompeted resistant cells, and blue compartments where only resistant cells were observed. Using image analysis algorithms we obtained the relative fluorescent intensity of both channels (illustrated in Figure 4F) and observed that, as predicted in the theoretical results shown in Figure 3A, the width of the channel

239 is correlated with the number of micro-environments where resistant cells have a higher fitness and
240 outcompete the susceptible subpopulation.

241 We recovered the bacteria from each well and centrifuged each sample into 1ml of liquid M9 without
242 nutrients and used a flow cytometer to validate the fraction of cells in each subpopulation estimated using
243 image analysis. Indeed, Figure 4E shows that in the low-connectivity regimes, the resistant subpopulation
244 outcompetes susceptible bacteria in micro-environments near the drug source. In contrast, when the
245 connectivity is high, susceptible bacteria can grow in a reduced number of compartments.

246 All together, we conclude that high connectivity between compartments in a linear array of micro-
247 environments enhances diffusion of drug molecules, increasing the strength of selection in favour of drug
248 resistance. In the following section we will extend this model to consider complex networks of connected
249 micro-environments.

250 **Population dynamics in complex networks of connected micro-environments**

251 To explore the generality of the result presented previously, we now remove the constraint that micro-
252 environments can only be connected linearly with a maximum of two neighbouring compartments.
253 As before, cells movement is not allowed but antibiotic molecules can diffuse between neighbouring
254 compartments. We then use the population dynamics model presented in equations 3a-d to evaluate the
255 effect of networks with different degrees of connectivity in the drug-resistance fitness landscape. Our goal
256 is to count the nodes in the network where drug resistance is positively selected for, that is the fraction of
257 the population locally exposed to drug concentrations within the mutant selection window.

258 First, we probed small networks with simple architectures and varying degrees of connectivity: a lattice, a
259 star, a wheel and a complete network.⁴⁸ We then introduced antibiotic in a random node of the network
260 at $t = 0$ and numerically solved the bacterial population dynamics model T units of time, in order to
261 estimate the total population density and the frequency of resistance of each node at $t = T$. It is important
262 to notice that, while in the previous section we used the width of the channel to quantify the connectivity
263 between two neighbouring nodes, we will now assume channel width between connected nodes is constant
264 and focus on a topological definition of connectivity. For instance, we could define *network density*
265 density based on the expression $2m/n(n-1)$, where n and m represent the number of nodes and edges of
266 the network, respectively. Other measures that quantify the modularity of the network, for instance the
267 network's clustering coefficient,⁴⁹ produce qualitatively the same results.

268 Figure 5A shows numerical results obtained after simulating 8000 random networks under a range of
269 antibiotic concentrations and parameter values described in Table 1. Each bar corresponds to the fraction
270 of nodes in the network colonized by each strain (cyan and yellow for resistant and susceptible strains,
271 respectively, and grey bars represent micro-environments where neither of the strains was able to grow).
272 In all cases, at low antibiotic concentrations, the susceptible strain colonized every micro-environment in
273 the network.

274 Our results suggest that networks with high degree of connectivity (e.g. a complete graph) allow for a
275 uniform distribution of antibiotics throughout every node in the graph, therefore effectively clearing both
276 populations. In contrast, in networks with intermediate connectivity (e.g. wheel and star), a gradient




Figure 5. Numerical simulations of the population dynamics model in networks with different topological properties. Antibiotic is deployed in a random node of the network and allowed to diffuse to neighbouring micro-environments. A) Fraction of colonized micro-environments by each strain as a function of antibiotic concentration: cyan and yellow bars represent resistant and susceptible bacteria, respectively. Grey bars represent that no growth was detected at the end of the experiment. From top to bottom: complete, wheel, star and cyclical networks. Note that networks with lower connectivity produce drug sanctuaries that allow for bacterial growth, even at high drug concentrations. B) Total bacterial density as a function of antibiotic concentration in random networks with different degrees of connectivity. We notice that bacterial density is negatively correlated with antibiotic concentration and network density. C) Frequency of resistance in the population is positively correlated with antibiotic concentration and network density.

of antibiotics is produced and some micro-environments present drug concentrations within the mutant selection window, even if the antibiotic is deployed at concentrations higher than the mutant prevention concentration. Interestingly, networks with low-connectivity (e.g. cycles), we observed drug sanctuaries where the antibiotic was present at very low concentrations, resulting in micro-environments colonized by susceptible bacteria. This is remarkable, given that the antibiotic was deployed at a very high dose.

Finally, in order to evaluate the evolutionary consequences of network topology on a large scale,⁵⁰ we tested the population dynamics that emerges in random networks with different degrees of connectivity.⁵¹ In particular, scale-free networks can be constructed algorithmically from the number of nodes n , the mean

285 degree k (an even integer) and a parameter β satisfying $0 \leq \beta \leq 1$. We can then computationally obtain
286 thousands of random undirected graph using the following recursive algorithm: first define a regular ring
287 lattice with n nodes, each connected to k neighbors ($k/2$ on each side, with edges uniformly distributed
288 among the nodes). Then, for node n_i , the edge (n_i, n_j) with $i < j$ is randomly rewired with probability β to
289 any other node to which n_i is not connected to. After producing each network, we estimated its density and
290 simulated the population dynamics that emerges in response to a random node of the network receiving a
291 lethal dose of antibiotics.

292 In Figures 5B and 5C we show results obtained after simulating ten thousand random networks of 100
293 nodes using different antibiotic concentrations. As expected, diffusion of antibiotics was increased in
294 networks with higher density, resulting in a larger number of nodes with drug concentration above the
295 mutant selection concentration. Consequently, we found that total bacterial density decreased as a function
296 of both network density and antibiotic concentration (Figure 5B). As previously argued, this decrease in
297 density is correlated, however, with an increased fraction of resistance in the population (Figure 5C).

298 Discussion

299 We presented a spatially-explicit population dynamics model to argue that diffusion of antibiotics in a
300 heterogeneous environment maximally suppresses growth of a bacterial population. Crucially, we also
301 found that spatial regimes with enhanced diffusion also strengthen selection for antibiotic resistance and,
302 as a result, increase the number of spatial locations with drug concentrations inside the mutant selection
303 window. This prediction was corroborated by growing a co-culture of fluorescently-tagged susceptible and
304 resistant strains in a 3D-printed gradient device and observing that the number of environments colonized
305 by the resistant sub-population increased as a function of the connectivity between compartments.

306 Previous studies have established that spatial structure can drive bacterial communication⁵² and modulate
307 diversity patterns in the population⁵³ and, in this context, it is not surprising that spatially-explicit
308 environments can produce a heterogeneous spatio-temporal distribution of genotypes.⁵⁴ A limitation
309 of our study is that we exclusively focused on the effect of drug gradients in the microbial population
310 dynamics, while ignoring that the interaction between bacteria and environment can be mediated by other
311 abiotic molecules. Indeed, previous theoretical and experimental studies have suggested that resource⁵⁵
312 and oxygen⁵⁶ gradients can also have a central role in driving diversity patterns and shaping the spatial
313 organization of microbial groups and their susceptibility to antimicrobial substances.⁵⁷

314 Cell migration has also been reported to be a key driver of microbial evolutionary dynamics,^{13,58} for
315 instance by allowing resistant cells to migrate upwards in an antibiotic gradient towards resource-rich
316 regions where susceptible cells cannot survive.²⁶ It is important to highlight that we purposefully designed
317 our culturing devices to allow diffusion of antibiotics through agar tunnels while blocking bacteria from
318 moving between compartments. This compartmentalization of the environment is a coarse representation
319 of the spatial structure found at multiple scales, from diverse tissue types in a single patient, to multiple
320 patients in a hospital, to communities with different health trends. Moreover, considering the environment
321 as a series of locally-homogeneous micro-environments is consistent with our modelling assumptions,
322 allowing us to use computer simulations to evaluate how, in the absence of migration, fitness landscapes

323 change in time and space.

324 Another simplification of our study is that we artificially produced drug gradients by deploying antibiotics
325 in a single location of the environment. Then, by modifying the width of the channel that joins neighbouring
326 compartments, we controlled the diffusion of antibiotic molecules between micro-environments. Of course,
327 the antibiotic gradient achieved with our experimental protocol is a simplification of the complex profile
328 of drug concentrations observed *in vivo* during antibiotic treatment. But we argue that the formation of
329 antibiotic gradients is ubiquitous and that a uniform spatial distribution of drugs is impossible to achieve
330 in practice. Actually, even if the initial distribution of antibiotics is homogeneous, antibiotic gradients can
331 be self-generated from the interaction between the microbial population and the extracellular environment,
332 for instance by the release of drug-degrading enzymes⁵⁹ or the absorption of antimicrobial molecules.⁶⁰

333 A consequence of presenting a non-uniform spatial distribution of genotypes is that bacterial communities
334 can implement collective strategies⁶¹ that would be evolutionary unstable in well-mixed environments,
335 notably metabolic cross-feeding,⁶² production of signalling molecules⁶³ and of extracellular matrix⁶⁴ that
336 enable the formation of biofilms⁶⁵ and the implementation of population-based resistance mechanisms.^{63,66}
337 Therefore we argue that spatial structure, being an inherent and unavoidable property of the environment,
338 is not only key to understand the evolutionary forces driving drug resistance adaptation, but also potentially
339 useful to decrease pathogenic virulence by disrupting quorum-sensing signalling^{52,67} or in the design of
340 spatially-targeted treatments that select against resistant genotypes.⁵⁸

341 **Materials and Methods**

342 **Bacterial strains and culture conditions**

343 For the competition assay between the resistant and susceptible bacteria to the antibiotic Kanamycin,
344 we used two *Escherichia coli* strains MC4100^{35,36} labeled with either YFP (GBY) for the susceptible
345 strain or CFP (WCL) for the resistant strain under a constitutive *PLac* promoter. We also use MG1655
346 as a non-resistant, non-fluorescent control strain. All experiments were conducted using M9 minimal
347 media supplemented with 0.4% of glucose and 0.2% of casaminoacids. Overnight cultures of WCL and
348 GBY strains were grown separately in M9 minimal media, as described above, at 30° C in continuous
349 shaking. After 20 hours of growth we measure optical density with a spectrophotometer and dilute the
350 sample with the highest OD to equalize the optical density for both cultures. Then we make a mixture at
351 1:1 ratio, 10 μ l of this co-culture is inoculated into each of the 96 well-plate with a range of Kanamycin
352 dilutions in M9 minimal media at fixed doses, and incubated again at 30° C for 20 hours. For the linear
353 array assay we filled each well with 200 μ l of soft M9 with nutrients as described above, for the first well
354 we add Kanamycin to the media (50 μ l/ml) and let them dry and diffused at 4° C for 48 hours. Then 10 μ l
355 of bacterial culture (in a mixture at 1:1 ratio) was added to each well. The device was placed inside a petri
356 dish, sealed with parafilm and incubated at 30° C for 24 hours.

357 **Fabrication of 3D-printed culture devices**

358 We used OpenScad to design culture devices composed of a linear array of micro-environments with
359 different degrees of connectivity. Devices were fabricated using a commercial 3D printer (Robo3D

R2) with polylactic acid (PLA). Each micro-environment and the channels that connect them were filled with semi-solid media (M9 + agar) allowing nutrients and antibiotic to move between neighbouring micro-environment by simple diffusion. Bacterial movement between micro-environments is prevented by independently inoculating the surface on each well with a 1:1 proportion of resistant and susceptible bacteria. CAD files for 3D printing can be downloaded from NIH 3D Print Exchange: <https://3dprint.nih.gov/discover/3dpx-011236>.

Flow cytometry

To estimate relative abundances of each strain using flow cytometry, first we collected the bacterial population of each well by scraping all the surface and vortexing it in minimal media without nutrients to remove the agar. We measured 10,000 events per sample using CFP (7/405-175 mW) and YFP (2/488-150 mW) fluorescent channels of an Image Streamx Amnis flow cytometer. Analysis was performed using Image Stream Data Analysis and Exploration Software (IDEAS).

Image acquisition and analysis

We used image acquisition system engineered using low-cost, open-source software and hardware (based on Arduino microcontrollers, <http://www.arduino.cc/>) and simple electronics components. This device controls a standard CCD camera (Canon EOS Rebel T6i with a 100mm macro lens) and produces time-lapse movies from multi-channel images (each frame is an array of images acquired using different fluorescent channels, exposures times, etc). Fluorescence is quantified using high intensity LEDs (Luxeon Star, <http://www.luxeonstar.com/>) and fluorescence imaging filters acquired from Thorlabs (Cyan: excitation 434nm and emission 479 nm, and Yellow: excitation 497nm and emission 535nm). Image analysis was performed using ImageJ (<https://imagej.nih.gov/ij/>). Design files and instructions to build the biological apparatus for fluorescence estimation used in this study can be downloaded from <https://github.com/ccg-esb-lab/baffle>

Acknowledgments

We thank Arne Traulsen and Michael Sieber for useful discussions and for hosting AFM for a semester. We also thank Remy Chait for inspiration and for providing the strains used in this study. This work was supported by PAPIIT-UNAM grants 201016 and IN209419.

Appendix

Table 1. Parameters used in the numerical solutions of the population dynamics model

Parameter	Value	Description
δ_A	0.2	antibiotic diffusion rate
δ_R	0.2	resource diffusion rate
ρ_*	$(1.4 \times 10^8, 1.05 \times 10^8)$	resource conversion coefficient (B_s, B_r)
μ_*	$(7.3 \times 10^{-10}, 8 \times 10^{-10})$	maximum uptake rate (B_s, B_r)
K_*	(1, 1)	half-saturation constant (B_s, B_r)
$\kappa_{1,*}$	(0.16, 0.055)	affinity for antibiotic (B_s, B_r)
$\kappa_{2,*}$	(0.04, 0.06)	maximal growth inhibition (B_s, B_r)
α_*	$(10 \times 10^{-10}, 10 \times 10^{-9})$	antibiotic degradation rate (B_s, B_r)

References

1. WHO, A. R. Global report on surveillance. *Antimicrobial Resistance, Global Report on Surveillance* (2014).
2. on Antimicrobial Resistance, R. *Securing new drugs for future generations: the pipeline of antibiotics* (Review on Antimicrobial Resistance, 2015).
3. Lee, C.-R., Cho, I., Jeong, B. & Lee, S. Strategies to minimize antibiotic resistance. *International journal of environmental research and public health* **10**, 4274–4305 (2013).
4. Meek, R. W., Vyas, H. & Piddock, L. J. V. Nonmedical uses of antibiotics: time to restrict their use? *PLoS biology* **13**, e1002266 (2015).
5. Stratton, C. W. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. *Emerging infectious diseases* **9**, 10 (2003).
6. Richards, H. *et al.* Spontaneous mutation rate is a plastic trait associated with population density across domains of life. *PLoS biology* **15**, e2002731 (2017).
7. Galhardo, R. S., Hastings, P. J. & Rosenberg, S. M. Mutation as a stress response and the regulation of evolvability. *Critical reviews in biochemistry and molecular biology* **42**, 399–435 (2007).
8. Pena-Miller, R. *et al.* When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. *PLoS biology* **11**, e1001540 (2013).
9. Read, A. F., Day, T. & Huijben, S. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. *Proceedings of the National Academy of Sciences* **108**, 10871–10877 (2011).
10. Geli, P., Laxminarayan, R., Dunne, M. & Smith, D. L. “one-size-fits-all”? optimizing treatment duration for bacterial infections. *PloS one* **7**, e29838 (2012).

- 412 **11.** Kouyos, R. D. *et al.* The path of least resistance: aggressive or moderate treatment? *Proceedings of*
413 *the Royal Society of London B: Biological Sciences* **281**, 20140566 (2014).
- 414 **12.** Hegreness, M., Shores, N., Damian, D., Hartl, D. & Kishony, R. Accelerated evolution of resistance
415 in multidrug environments. *Proceedings of the National Academy of Sciences* (2008).
- 416 **13.** Baym, M., Stone, L. K. & Kishony, R. Multidrug evolutionary strategies to reverse antibiotic
417 resistance. *Science* **351**, aad3292 (2016).
- 418 **14.** Kim, S., Lieberman, T. D. & Kishony, R. Alternating antibiotic treatments constrain evolutionary
419 paths to multidrug resistance. *Proceedings of the National Academy of Sciences* **111**, 14494–14499
420 (2014).
- 421 **15.** Imamovic, L. & Sommer, M. O. Use of collateral sensitivity networks to design drug cycling protocols
422 that avoid resistance development. *Science translational medicine* **5**, 204ra132–204ra132 (2013).
- 423 **16.** Fuentes-Hernandez, A. *et al.* Using a sequential regimen to eliminate bacteria at sublethal antibiotic
424 dosages. *PLoS biology* **13**, e1002104 (2015).
- 425 **17.** Beardmore, R. E., Peña-Miller, R., Gori, F. & Iredell, J. Antibiotic cycling and antibiotic mixing:
426 which one best mitigates antibiotic resistance? *Molecular biology and evolution* **34**, 802–817 (2017).
- 427 **18.** McAdams, D., Waldetoft, K. W., Tedijanto, C., Lipsitch, M. & Brown, S. P. Resistance diagnostics
428 as a public health tool to combat antibiotic resistance: A model-based evaluation. *bioRxiv* 452656
429 (2018).
- 430 **19.** Deresinski, S. Vancomycin in combination with other antibiotics for the treatment of serious
431 methicillin-resistant *Staphylococcus aureus* infections. *Clin Infect Dis* **49**, 1072–1079 (2009).
- 432 **20.** Solas, C., Lafeuillade, A., Halfon, P., Hittinger, G. & Lacarelle, B. Discrepancies between Protease
433 Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency
434 Virus-Infected Patients Discrepancies between Protease Inhibitor Concentrations and Viral
435 Load in Reservoirs and Sanctuary S. *Antimicrob Agents Chemother* **47**, 238–243 (2003).
- 436 **21.** Moreno-Gamez, S. *et al.* Imperfect drug penetration leads to spatial monotherapy and rapid evolution
437 of multidrug resistance. *Proceedings of the National Academy of Sciences* 201424184 (2015).
- 438 **22.** Nosanchuk, J. D., Lin, J., Hunter, R. P. & Aminov, R. I. Low-dose antibiotics: current status and
439 outlook for the future. *Frontiers in microbiology* **5**, 478 (2014).
- 440 **23.** Arnoldini, M. *et al.* Bistable expression of virulence genes in salmonella leads to the formation of an
441 antibiotic-tolerant subpopulation. *PLoS biology* **12**, e1001928 (2014).
- 442 **24.** Gullberg, E. *et al.* Selection of resistant bacteria at very low antibiotic concentrations. *PLoS pathogens*
443 **7**, e1002158 (2011).
- 444 **25.** Andersson, D. I. & Hughes, D. Microbiological effects of sublethal levels of antibiotics. *Nature*
445 *Reviews Microbiology* **12**, 465 (2014).

- 446 **26.** Hermesen, R., Deris, J. B. & Hwa, T. On the rapidity of antibiotic resistance evolution facilitated by a
447 concentration gradient. *Proceedings of the National Academy of Sciences* **109**, 10775–10780 (2012).
- 448 **27.** Greulich, P., Waclaw, B. & Allen, R. J. Mutational pathway determines whether drug gradients
449 accelerate evolution of drug-resistant cells. *Physical review letters* **109**, 088101 (2012).
- 450 **28.** Zhang, Q. *et al.* Acceleration of emergence of bacterial antibiotic resistance in connected microenvi-
451 ronments. *Science* **333**, 1764–1767 (2011).
- 452 **29.** Gralka, M., Fusco, D., Martis, S. & Hallatschek, O. Convection shapes the tradeoff between antibiotic
453 efficacy and the selection for resistance in spatial gradients. *Physical Biology (in review)* **14**, 2–7
454 (2017).
- 455 **30.** Tecon, R. *et al.* Bridging the holistic-reductionist divide in microbial ecology. *mSystems* **4** (2019).
- 456 **31.** Tenaillon, O. *et al.* The molecular diversity of adaptive convergence. *Science* **335**, 457–461 (2012).
- 457 **32.** Zoz, F. *et al.* Control of relative air humidity as a potential means to improve hygiene on surfaces: a
458 preliminary approach with *listeria monocytogenes*. *PLoS One* **11**, e0148418 (2016).
- 459 **33.** Lowery, N. V. & Ursell, T. Structured environments fundamentally alter dynamics and stability of
460 ecological communities. *Proceedings of the National Academy of Sciences* 201811887 (2018).
- 461 **34.** Or, D., Smets, B. F., Wraith, J., Dechesne, A. & Friedman, S. Physical constraints affecting bacterial
462 habitats and activity in unsaturated porous media—a review. *Advances in Water Resources* **30**, 1505–
463 1527 (2007).
- 464 **35.** Chait, R., Craney, A. & Kishony, R. Antibiotic interactions that select against resistance. *Nature* **446**,
465 668 (2007).
- 466 **36.** Chait, R., Shrestha, S., Shah, A. K., Michel, J.-B. & Kishony, R. A differential drug screen for
467 compounds that select against antibiotic resistance. *PloS one* **5**, e15179 (2010).
- 468 **37.** Melnyk, A. H., Wong, A. & Kassen, R. The fitness costs of antibiotic resistance mutations. *Evolution-*
469 *ary applications* **8**, 273–283 (2015).
- 470 **38.** Drlica, K. & Zhao, X. Mutant selection window hypothesis updated. *Clinical infectious diseases* **44**,
471 681–688 (2007).
- 472 **39.** Eagle, H. & Musselman, A. The rate of bactericidal action of penicillin in vitro as a function of its
473 concentration, and its paradoxically reduced activity at high concentrations against certain organisms.
474 *Journal of Experimental Medicine* **88**, 99–131 (1948).
- 475 **40.** Pena-Miller, R., Fuentes-Hernandez, A., Reding, C., Gudelj, I. & Beardmore, R. Testing the optimality
476 properties of a dual antibiotic treatment in a two-locus, two-allele model. *Journal of The Royal Society*
477 *Interface* **11**, 20131035 (2014).
- 478 **41.** Engelstädter, J. Fitness landscapes emerging from pharmacodynamic functions in the evolution of
479 multidrug resistance. *Journal of evolutionary biology* **27**, 840–853 (2014).

- 480 **42.** Regoes, R. R. *et al.* Pharmacodynamic functions: a multiparameter approach to the design of antibiotic
481 treatment regimens. *Antimicrobial agents and chemotherapy* **48**, 3670–3676 (2004).
- 482 **43.** Peña-Miller, R., Lähnemann, D., Schulenburg, H., Ackermann, M. & Beardmore, R. Selecting against
483 antibiotic-resistant pathogens: optimal treatments in the presence of commensal bacteria. *Bulletin of*
484 *mathematical biology* **74**, 908–934 (2012).
- 485 **44.** Kepler, T. B. & Perelson, A. S. Drug concentration heterogeneity facilitates the evolution of drug
486 resistance. *Proceedings of the National Academy of Sciences* **95**, 11514–11519 (1998).
- 487 **45.** Baquero, F. & Negri, M. C. Selective compartments for resistant microorganisms in antibiotic
488 gradients. *BioEssays : news and reviews in molecular, cellular and developmental biology* **19**, 731–6
489 (1997).
- 490 **46.** Mira, P. M., Meza, J. C., Nandipati, A. & Barlow, M. Adaptive landscapes of resistance genes change
491 as antibiotic concentrations change. *Molecular Biology and Evolution* **32**, 2707–2715 (2015).
- 492 **47.** Neches, R. Y., Flynn, K. J., Zaman, L., Tung, E. & Pudlo, N. On the intrinsic sterility of 3d printing.
493 *PeerJ* **4**, e2661 (2016).
- 494 **48.** Askari, M., Miraghaei, Z. M. & Samani, K. A. The effect of hubs and shortcuts on fixation time in
495 evolutionary graphs. *Journal of Statistical Mechanics: Theory and Experiment* **2017**, 073501 (2017).
- 496 **49.** Opsahl, T. & Panzarasa, P. Clustering in weighted networks. *Social networks* **31**, 155–163 (2009).
- 497 **50.** Allen, B. *et al.* Evolutionary dynamics on any population structure. *Nature* **544**, 227 (2017).
- 498 **51.** Watts, D. J. & Strogatz, S. H. Collective dynamics of ‘small-world’ networks. *nature* **393**, 440 (1998).
- 499 **52.** Kim, M. K., Ingremeau, F., Zhao, A., Bassler, B. L. & Stone, H. A. Local and global consequences of
500 flow on bacterial quorum sensing. *Nature microbiology* **1**, 15005 (2016).
- 501 **53.** Rainey, P. B. & Travisano, M. Adaptive radiation in a heterogeneous environment. *Nature* **394**, 69–72
502 (1998).
- 503 **54.** Legrand, D. *et al.* Eco-evolutionary dynamics in fragmented landscapes. *Ecography* **40**, 9–25 (2017).
- 504 **55.** Mitri, S., Clarke, E. & Foster, K. R. Resource limitation drives spatial organization in microbial
505 groups. *The ISME Journal* **10**, 1471–1482 (2016).
- 506 **56.** Chen, J. *et al.* Impacts of chemical gradients on microbial community structure. *The ISME Journal*
507 **11**, 920–931 (2017).
- 508 **57.** Sinclair, P., Carballo-Pacheco, M. & Allen, R. J. Growth-dependent drug susceptibility can prevent or
509 enhance spatial expansion of a bacterial population. *Physical biology* **16**, 046001 (2019).
- 510 **58.** Okamoto, K. W., Post, D. M., Vasseur, D. A. & Turner, P. E. Managing the emergence of pathogen
511 resistance via spatially targeted antimicrobial use. *Evolutionary Applications* **11**, 1822–1841 (2018).

- 512 **59.** Yurtsev, E. A., Chao, H. X., Datta, M. S., Artemova, T. & Gore, J. Bacterial cheating drives the
513 population dynamics of cooperative antibiotic resistance plasmids. *Molecular systems biology* **9**, 683
514 (2013).
- 515 **60.** Snoussi, M. *et al.* Heterogeneous absorption of antimicrobial peptide ll37 in escherichia coli cells
516 enhances population survivability. *eLife* **7**, e38174 (2018).
- 517 **61.** Peña, J., Wu, B., Arranz, J. & Traulsen, A. Evolutionary Games of Multiplayer Cooperation on
518 Graphs. *PLoS Computational Biology* **12**, 1–15 (2016).
- 519 **62.** Pande, S. *et al.* Privatization of cooperative benefits stabilizes mutualistic cross-feeding interactions
520 in spatially structured environments. *The ISME Journal* **10**, 1413–1423 (2016).
- 521 **63.** Lee, H. H., Molla, M. N., Cantor, C. R. & Collins, J. J. Bacterial charity work leads to population-wide
522 resistance. *Nature* **467**, 82 (2010).
- 523 **64.** Nadell, C. D., Ricaurte, D., Yan, J., Drescher, K. & Bassler, B. L. Flow environment and matrix
524 structure interact to determine spatial competition in *Pseudomonas aeruginosa* biofilms. *eLife* 1–13
525 (2017).
- 526 **65.** Flemming, H.-C. *et al.* Biofilms: an emergent form of bacterial life. *Nature Reviews Microbiology* **14**,
527 563 (2016).
- 528 **66.** Estrela, S. & Brown, S. P. Community interactions and spatial structure shape selection on antibiotic
529 resistant lineages. *PLoS computational biology* **14**, e1006179 (2018).
- 530 **67.** Maeda, T. *et al.* Quorum quenching quandary: resistance to antivirulence compounds. *The ISME*
531 *journal* **6**, 493 (2012).